RJV Stock Chart & Stats
€0.33
€0.02(6.30%)
At close: 4:00 PM EST
€0.33
€0.02(6.30%)
Day’s Range― - ―
52-Week Range€0.28 - €0.50
Previous CloseN/A
Volume0.00
Average Volume (3M)46.00
Market Cap
€70.08M
Enterprise Value€116.48M
Total Cash (Recent Filing)€18.03M
Total Debt (Recent Filing)€14.01M
Price to Earnings (P/E)―
Beta0.93
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding219,083,250
10 Day Avg. Volume0
30 Day Avg. Volume46
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)2.97
Price to Sales (P/S)1.24
P/FCF Ratio25.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.61Price Target Upside84.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent revenue expansion (latest +11.22%) indicates durable demand for SomnoMed’s oral appliance therapy across its markets. Sustainable top-line growth supports scaling of fixed costs, continued investment in channels and product development, and helps fund a path toward profitability over several quarters.
High Gross MarginsA roughly 60% gross margin reflects structural production and pricing advantages in custom mandibular advancement splints. High product-level margins provide room to absorb SG&A, invest in distribution or R&D, and improve operating leverage as revenue grows, aiding sustainable margin expansion over months.
Improved Cash GenerationA >562% jump in free cash flow and positive operating cash flow despite accounting losses show strong cash conversion. This durable cash generation provides flexibility to fund working capital, selective investment or clinical/commercial expansion without heavy external financing over the medium term.
Bears Say
Negative ProfitabilityPersistent negative net profit and EBIT margins mean the business is not yet operationally profitable. Unless margins improve through higher volumes, price mix or reduced overhead, ongoing losses can erode cash cushions and limit the company’s ability to reinvest for growth over the coming 2-6 months.
Negative Return On EquityA negative ROE indicates shareholder capital is currently not earning positive returns, signalling inefficient capital deployment or heavy upfront investment. Even with low leverage, sustained negative ROE can weigh on investor appetite and constrain access to growth capital if losses persist.
No Dividend Policy / Limited Shareholder ReturnsAbsence of a dividend alongside ongoing unprofitability implies limited near-term cash returns to shareholders. For investors seeking income or distributions, this structural lack of payout policy reduces the stock’s appeal until consistent profitability and surplus cash generation are established.
Somnomed Limited News
RJV FAQ
What was Somnomed Limited’s price range in the past 12 months?
Somnomed Limited lowest stock price was €0.28 and its highest was €0.50 in the past 12 months.
What is Somnomed Limited’s market cap?
Somnomed Limited’s market cap is €70.08M.
When is Somnomed Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Somnomed Limited’s earnings last quarter?
Currently, no data Available
Is Somnomed Limited overvalued?
According to Wall Street analysts Somnomed Limited’s price is currently Undervalued.
Does Somnomed Limited pay dividends?
Somnomed Limited does not currently pay dividends.
What is Somnomed Limited’s EPS estimate?
Somnomed Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Somnomed Limited have?
Somnomed Limited has 219,083,250 shares outstanding.
What happened to Somnomed Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Somnomed Limited?
Currently, no hedge funds are holding shares in DE:RJV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Somnomed Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
181.70%
12-Months-Change
Fundamentals
Return on Equity
-5.31%
Trailing 12-Months
Asset Growth
14.75%
Trailing 12-Months
Company Description
Somnomed Limited
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient’s mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient’s upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances. SomnoMed Limited was incorporated in 1987 and is headquartered in Crows Nest, Australia.
RJV Company Deck
RJV Earnings Call
Q2 2026
0:00 / 0:00
RJV Stock 12 Month Forecast
Average Price Target
€0.61
▲(84.64% Upside)
Technical Analysis
Options Prices
Currently, No data available
---